Esperion Therapeutics, INC Form 4 insider transactions

Esperion Therapeutics CEO Sheldon L. Koenig sold 28,427 shares of common stock at $2.788 per share to cover tax obligations on vested restricted stock units.

Esperion Therapeutics CFO Benjamin Halladay sold 7,046 shares of common stock at $2.808 per share to cover tax obligations on vested restricted stock units.

Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, reported a planned sale of 11 common shares on July 17, 2025, at $1.115 per share to cover tax obligations on vested restricted stock units.

Esperion Therapeutics' General Counsel, Benjamin Looker, sold 1,304 shares of common stock to cover tax obligations related to vested restricted stock units.

Esperion Therapeutics, Inc. Director John Craig Thompson was granted 40,000 stock options with a $1 exercise price, vesting over three years.

Esperion Therapeutics' General Counsel, Benjamin Looker, sold 6,422 shares of common stock on June 17, 2025, at $1.152 per share to satisfy tax obligations on vested restricted stock units.

Esperion Therapeutics' President and CEO, Sheldon L. Koenig, sold 30,474 shares of common stock to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 7,229 shares of common stock at $1.152 per share on June 17, 2025, to satisfy tax obligations related to vested restricted stock units, as disclosed in a Form 4 filing.

Esperion Therapeutics, Inc. Director J. Martin Carroll was granted 33,000 shares of common stock and 44,000 stock options, signaling continued alignment with shareholder interests.

Esperion Therapeutics, Inc. Director Seth H. Fischer has acquired 33,000 shares of common stock and 44,000 stock options, signaling a potential vote of confidence in the company's future.

Esperion Therapeutics, Inc. Director Robert E. Hoffman was granted 5,280 shares of common stock and options to purchase 7,040 shares, with vesting tied to future dates or the company's next annual meeting.

Esperion Therapeutics, Inc. Director Stephen Rocamboli acquired 33,000 shares of common stock and 44,000 stock options on May 29, 2025, significantly increasing his beneficial ownership in the company.

Esperion Therapeutics, Inc. Director Jay Shepard has increased his beneficial ownership by acquiring 33,000 shares of common stock and 44,000 stock options, signaling a strengthened alignment with shareholder interests.

Esperion Therapeutics, Inc. Director Nicole Vitullo was granted 88,000 stock options with an exercise price of $0.87, as disclosed in a recent SEC Form 4 filing.

Esperion Therapeutics, Inc. Director Tracy M. Woody has reported the acquisition of 88,000 stock options with an exercise price of $0.87, aligning her incentives with the company's performance.

Chief Commercial Officer of Esperion Therapeutics, Eric Warren, sold 108 shares of common stock on April 17, 2025, to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics' CFO, Benjamin Halladay, sold 8 shares of common stock on April 17, 2025, at a price of $0.964 per share to satisfy tax obligations related to vested restricted stock units.

Director Robert E. Hoffman of Esperion Therapeutics, Inc. was granted stock options to purchase 40,000 shares of common stock on April 1, 2025.

Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 3,535 shares of common stock on March 18, 2025, to satisfy tax obligations related to vested restricted stock units.

Chief Commercial Officer Eric Warren sold 2,433 shares of Esperion Therapeutics stock on March 18, 2025, to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics CEO Sheldon L. Koenig sold 13,047 shares of common stock on March 18, 2025, at a price of $1.504 per share to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics CEO, Sheldon L. Koenig, reports acquisition of 840,000 common stock shares and 753,000 stock options on March 14, 2025.

Esperion Therapeutics' CFO, Benjamin Halladay, reports the acquisition of stock and option awards, along with shares acquired through the Employee Stock Purchase Plan.

Chief Commercial Officer Eric Warren of Esperion Therapeutics reports the acquisition of stock and options, signaling changes in his beneficial ownership.

Benjamin Looker, General Counsel of Esperion Therapeutics, acquired shares and stock options in a transaction dated March 14, 2025.

Esperion Therapeutics' Chief Commercial Officer, Eric Warren, sold 239 shares of common stock on February 19, 2025, to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 11 shares of common stock on February 19, 2025, at a price of $1.86 per share to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 9 shares of common stock to cover tax obligations related to vested restricted stock units.

Esperion Therapeutics' Chief Commercial Officer, Eric Warren, sold 123 shares of common stock at $2.26 per share to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 3,245 shares of common stock on December 17, 2024, to satisfy tax obligations related to vested restricted stock units.